It was quite a welcome surprise to learn that the Pfizer/BioNTech COVID-19 vaccine (BNT162b1) is showing greater than 90% efficacy in preventing SARS-CoV-2 infection. This vaccine is one of several mRNA-based vaccines that were recently in phase 3 clinical trials, including the one from Moderna. The questions now on everybody’s mind are: Is it safe? And when will it become available?
Brad Gibson, Ph.D., is our behind-the-scenes scientific consultant, who still writes very occasionally. As a former Professor at the Buck Institute for Research on Aging, Brad’s work was focused on understanding the biological and chemical processes that are common to both age-related diseases and aging. Prior to that he was a Professor of Pharmaceutical Chemistry at UCSF from 1985-2000, where he worked on various biomedical research projects including infectious diseases and structural biology. Brad joined Amgen in 2016, a California-based biotechnology and pharmaceutical company, where he is currently a Director of Therapeutic Discovery. Brad received his PhD in Analytical Chemistry from the Massachusetts Institute of Technology in 1984 and then took a postdoctoral fellowship in Chemistry at Cambridge University in England before joining the faculty at UCSF in 1985.
Subscribe to Yoga for Healthy Aging by Email ° Follow Yoga for Healthy Aging on Facebook ° To order Yoga for Healthy Aging: A Guide to Lifelong Well-Being, go to Amazon, Shambhala, Indie Bound or your local bookstore.